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Abstract
Metachromatic leukodystrophy (MLD) is a recessive autosomal disease which is characterized by an accumulation
of sulfatides in the central and peripheral nervous system. It is due to the enzyme deficiency of the sulfatide
sulfatase i.e. arylsulfatase A (ASA). we studied 5/200 cases of MLD and clearly distinguished three clinical forms.
One of them presented the juvenile form; two presented the late infantile form; and two other presented the adult
form. The Magnetic Resonance Imaging (MRI) of these patients showed a diffuse, bilateral and symmetrical
demyelination. The biochemical diagnosis of MLD patients evidencing the low activity of ASA and sulfatide
accumulation.
Virtual slides: The virtual slide(s) for this article can be found here:
http://www.diagnosticpathology.diagnomx.eu/vs/1791578262610232
Patients and methods: We studied 5/200 MLD patients addressed to us for behavioral abnormalities and
progressive mental deterioration. All of them were diagnosed at first by brain MRI evidencing a bilateral
demyelination, then the measurement of ASA activity using P-nitrocathecol sulfate as substrate, finally the
sulfatiduria was performed using thin-layer chromatography using alpha-naphtol reagent.
Results: In this study, from 200 patients presenting behavioral abnormalities and a progressive mental
deterioration, we reported just 2 patients were diagnosed as late-infantile form of MLD. Only1 case presented as
the juvenile form; and 2 patients with the adult-type of MLD. The brain magnetic resonance imaging (MRI) of all
patients showed characteristic lesions of MLD with extensive demyelination. Biochemical investigations of these
patients detected a low level of ASA activity at 0°C and 37°C; the excess of sulfatide in sulfatiduria.
Conclusion: MRI is required to orient the diagnosis of MLD patients; the latter must be confirmed by the
biochemical investigations which is based on the measurement of ASA activity and the excess of sulfatide showed
in the sulfatiduria.
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Background
Metachromatic leukodystrophy or scholz’sd i s e a s ei sa n
autosomal recessively inherited lysosomal storage disor-
der caused by the deficiency of arylsulfatase A (ASA).
This enzyme catalyses the first degradation step of the
glycosphingolipid 3-O-sulfogalactosylceramide (sulfa-
tide). Sulfatide accumulates in white matter of the cen-
tral nervous system and peripheral nerves as a result of
ASA deficiency and leads to progressive demyelination
and lethal neurological symptoms. Visceral organs with
an excretory function such a kidney and gallbladder also
store sulfatide but not so much affected functionally [1].
MLD is divided into three major clinical forms
according to the age of onset. The most frequent and
fatal form is the late-infantile form which starts before 4
years of age and patients die by the end of the first dec-
ade. The juvenile form of MLD includes age onset
between 4 and 16 years, while symptoms of adult MLD
start after puberty. In a few patients, MLD results from
deficiency of the activator protein saposin B (SAP-B) [2].
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for MLD, and the easy enzymatic detection of ASA defi-
ciency, this disease has been considered as affecting only
children at the walking period, this neuropathology is
characterized by a regression of previous acquisitions
related to dys and demyelination [3]. More precise data on
the topographical sequences of myelination in humans has
been recently developed by Magnetic Resonance Imaging.
The aim of this study is to underline the value of MRI
for MLD diagnosis orientation and the interest of the
biochemical study that involves the measurement of
ASA activity and sulfatiduria to confirm MLD diagnosis.
Patients and methods
The patients in this study were unrelated and originated
from different geographic areas of Tunisia. This study
was approved by ethics committees of the respective
Tunisian hospitals, and the families gave informed con-
sent before withdrawal of blood. The studied patients
were addressed to us for behavioral abnormalities and a
progressive mental deterioration. The patients were
always consanguineous.
Family and history description of the 5 studied
patients were summarized in table 1.
Cases with late-infantile form
Patient: M.A.N
This boy was born as a child of healthy first degree con-
sanguineous parents originated from the Sahel of Tuni-
sia (Teboulba). The patient was delivered vaginally after
an uncomplicated full-term pregnancy. He was admitted
to the pediatric department of CHU Fattouma Bour-
guiba of Monastir at 3 years. He had difficulty in walk-
ing, nystagmus, spontaneous contraction at extremities.
He had mental-motor retardation and was diagnosed as
late infantile form of MLD with low ASA activity and
the excess of sulfatide showed in his sulfatiduria profile.
His brain MRI indicated characteristic lesions of MLD
in the white matter; Figure 1 and Figure 2.
Patient: K.H
This girl of 2 years was referred to the pediatric depart-
ment of Nabeul hospital in the northern-west region of
Tunisia. She was diagnosed as late infantile MLD; she
had the same symptoms as the previous case, difficulty
in walking, spontaneous contraction at extremities. She
also had mental-motor retardation with low ASA activ-
i t ya n dt h ec h r o m a t o g r a p h i cp r o f i l eo fs u l f a t i d u r i a
revealed the same excess of sulfatides showed in the
first case. Her brain MRI showed the same lesions
demonstrated in the first patient; Figure 1 and Figure 2.
Case with juvenile form
Patient: R.Y
This little girl whose parents were first cousin was the
second child, after a normal vaginal delivery. By the age
of 5 years, this girl was evaluated for difficulty in walk-
ing at pediatric department of Sfax hospital in Southern
Tunisia. After that, she lost her abilities of sitting, eating
and swallowing. She had epileptic seizures, optic atrophy
and spasticity. She was diagnosed as juvenile form of
MLD on the basis of clinical analysis and the diagnosis
was demonstrated by decreased ASA activity. Her
Table 1 Description of the 5 MLD patients.
Features Patient F.S. Patient S.C. Patient Y.R. Patient N.M.A Patient K.H.
Consanguinity of the parents/degree -1
stdegree 1
stdegree 1
stdegree 1
stdegree
Age of diagnosis (yr) 43 yr 34 yr 4 yr 3 yr 2 yr
Age of onset (yr) 42 yr 33 yr 4 yr 3 yr 2 yr
Sex female Female Female Male Female
Age (yr) Died at 44 yr 34 yr 5 yr 4 yr 3 yr
ASA activity at 37°C (UV: 12-35 μkat/Kg of Proteine) 7661 04
ASA activity at 0°C (UV: 3-9 μkat/Kg of Proteine) 122 1 2
Qualitative sulfatiduria Presence of an abnormal band of 3-O-sulfogalactosylceramide (sulfatide)
yr: year, UV: usual value
Figure 1 The sulfatiduria profile of the patient compared with
a control.
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patients with late infantile form. Her brain MRI showed
characteristic lesions of MLD; Figure 1, Figure 3.
Cases with adult form
Patient: S.F
A 43-year-old female, originated from the Sahel of Tuni-
sia (Mahdia), presented a history of primary sterility. She
was admitted to the neurological service of CHU Fat-
touma Bourguiba of Monastir for behavioural modifica-
tions, she showed gradual obvious dementing symptoms
such as memory disturbance and disorientation. We
also detected some neurological signs, i.e. pyramidalor
cerebellar syndrome and peripheral neuropathy. The
cognitive deficits encompassed several cognitive domains
including memeory, visio-spatial, and executive func-
tions indicating widespread organic lesions, and based
on the initial brain MRI, evidencing a diffuse bilateral
demyelination often symmetrical, sometimes limited to
the periventricular areas and respecting U fibres; Figure
4. Her ASA activity in peripheral blood leukocytes was
decreased at 0°C and 37°C, the sulfatiduria profile
revealed the excess of sulfatides like other cases; Figure
1. This patient died at 44 years old.
Patient: C.S
A 34-year-old female was referred to the neurological
department of Fattouma Bourguiba Hospital of Monastir
(Sahel). She presented both mental deterioration and
behavioural modifications at the onset of the disease.
These modifications lead her to psychiatric institutions.
During evolution, other modifications appeared such as
memory dysfunction, ideation difficulties, spatio-tem-
poral disorientation, and loss of sense of judgement.
The brain MRI showed the same lesions of the patient
S.F; Figure 4. During evolution, the patient had
increased motor and cerebellar symptoms. This lead to
biological investigations, her ASA activity was low and
Figure 2 Brain MRI of the patient with late infantile form of
MLD.
Figure 3 Brain MRI of the patient with juvenile form of MLD.
Figure 4 Brain MRI of the patient with adult form of MLD
‘arrows’ indicate the lesions of the white matter.
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fatide like the other patients; Figure 1.
Methods
ASA activity determination in leukocytes
ASA was determined in leukocytes which were isolated
from blood samples of patients and homogenized by
three times of freeze-thawing [4]. Proteins were deter-
mined in leukocytes homogenates according to the
method of lowry using bovine serum albumin as stan-
dard. ASA activity was determined in leukocyte homo-
genates that contain 100-400 μg protein using p-
nitrocathecol sulfate (sigma Chemical Co.,USA) as sub-
strate [5].
The excess of sulfatides must be evidenced to confirm
the diagnosis as there are pseudo-deficiencies of ASA: it
was either detected on a peripheral nerve biopsy show-
ing characteristic metachromatic deposits, or more easily
looking for sulfatiduria in urine [6].
Qualitative sulfatiduria
This method was performed as followed: a 10 ml fresh
urine sample was collected; 2 drops of concentrated
acetic acid were added, after that the sample was left
overnight in the cold; the pellet obtained after centrifu-
gation 10 min at 2500 rpm, was collected and extracted
by 5 ml chloroform/methanol 2:1 (v/v). After sonication,
1 ml distilled water was added; after mixing throughly
and centrifugation, the upper phase contained urinary
salts, and the lower phase, the lipid extract. The latter
was evaporated to dryness and redissolved in 100 μlo f
chloroform:methanol 2:1for chromatography on silica-
gel thin-later plates in chloroform:methanol:water
70:30:4 by volume; the revelation of the sulfatide glycoli-
pid was done using alphanaphtol reagent [7,8].
Results
In This study, we estimated for the first time in Tunisia,
the incidence of this neuropathology in our studied
population; we founded just 5/200 cases representing
the three MLD phenotypes. All suspected patients have
a collapsed ASA activity in leukocyte homogenate and
their chromatographic profiles were similar and revealed
the presence of an abnormal band corresponding to the
excess of 3-O-sulfogalactosylceramide and their brain
MRI showed characteristics lesions of the three MLD
forms in the white matter.
Discussion
The MLD is a lysosomal storage disease, resulting
mainly from ASA deficiency which is essential for the
degradation of sulfatides. Three clinical forms have been
described: the infantile form, the juvenile form and the
adult form. The disparity of these phenotypes reflects
the difficulty of the clinical, biological and paraclinical
diagnostic. The study of heterozygous subjects by deter-
mination of enzyme activity is limited because there is
an overlap between the values of ARSA activity in nor-
mal subjects and heterozygous [9]. In some clinically
healthy subjects or suffering from other neurological
diseases than the MLD, enzyme activity observed may
be collapsed, associated with PD alleles. These alleles
represent 7-15% of alleles in the general population. PD
in the ARSA must be recognized to avoid misdiagnosis
and for prenatal diagnosis in families which coexists one
allele of MLD [10].
The prenatal diagnosis is the best way to put hetero-
zygous couple to the disease, especially in a couple who
had an affected child (index case). Currently, the identi-
fication of fetal genotype and predicting the type of the
disease even in the absence of family history has become
easier with the use of molecular technologies [11]. It is
important to note that molecular diagnosis of MLD is
more accurate and uses sample more stable than those
used for determining enzyme activity. A molecular study
is necessary to screen for the mutations causing differ-
ent forms of this neuropathology. The characterization
of these mutations allows us to clarify the genotype/phe-
notype correlations, to improve the quality of genetic
counseling [12].
The conventional therapeutic approaches are essen-
tially symptomatic. They were made in order to restore
the arylsulfatase A activity and prevent the progression
of the pathological accumulation of sulfatides and con-
sequently reduce morbidity associated with MLD. The
aim of enzymatic therapy is to administer MLD patient
with active enzyme, this approach will be the future of
metachromatic leukodystrophy [13].
Conclusion
The lysosomal storage diseases, especially the sphingoli-
pidoses, presented a great clinical variability which com-
plicated the diagnosis. According this study, the brain
magnetic resonance imaging (MRI) was required to ori-
ent the diagnosis of MLD patients. The biochemical
investigations such as the measurement of ASA activity
and qualitative sulfatiduria were necessary to confirm
MLD diagnosis. It is important to note that according
this work, we estimated for the first time in Tunisia, the
incidence of this neuropathology in our studied popula-
tion; we found just 5/200 cases representing the three
phenotypes of MLD.
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